15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 5 firms covering Supernus Pharmaceuticals Inc, 4 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $55.00 to $67.00, so the covering firms are broadly aligned. The average target of $62.40 sits 31% above the current $47.73. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.66 next quarter toward $4.34 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 ratings
Moderate Buy
Strong Buy00%
Buy480%
Hold120%
Sell00%
Strong Sell00%
Based on 5 analysts giving stock ratings to Supernus Pharmaceuticals Inc.
As of Jul, 4 of 5 firms rate SUPN a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
SUPN EPS & revenue forecast
EPS · NEXT QUARTER
$0.66
Range $0.59 – $0.74 · 3 analysts · +9% YoY
Next period, 3 analysts expect Supernus Pharmaceuticals Inc to earn $0.66 a share (range $0.59 – $0.74), versus $0.61 a year earlier. Full-year consensus is $2.49, growing to $4.34 the year after.
REVENUE · NEXT QUARTER
$219.0M
Range $211.0M – $223.3M · 3 analysts · +14% YoY
Revenue is expected to reach $219.0M (range $211.0M – $223.3M), +14.0% year-over-year. Full-year consensus is $867.2M, rising to $1.0B next year.
Top analysts covering Supernus Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on SUPN.
#1
David Amsellem
Piper Sandler · Rank #95
Buy
$65.00+36.2% to target
Overall win rate
50%
+ Follow
#2
Kristen Kluska
Cantor Fitzgerald · Rank #162
Buy
$67.00+40.4% to target
Overall win rate
38%
+ Follow
#3
Annabel Samimy
Stifel
Hold
$55.00+15.2% to target
Coverage
—
+ Follow
#4
SK
Stacy Ku
TD Cowen
Buy
$65.00+36.2% to target
Coverage
—
+ Follow
#5
PP
Pavan Patel
B of A Securities
Buy
$65.00+36.2% to target
Coverage
—
+ Follow
SUPN stock forecast FAQ
What is SUPN's average 12-month price target?+
The 5 analysts with a live target average $62.40 for Supernus Pharmaceuticals Inc over the next 12 months, ranging from a $67.00 high to a $55.00 low.
Is SUPN stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 5 analyst ratings, 4 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for SUPN?+
The Street-high target is $67.00 (Cantor Fitzgerald), and the Street-low is $55.00 (Stifel). The average of all 5 active targets is $62.40.
How many Wall Street analysts cover SUPN?+
5 analysts have an active rating on Supernus Pharmaceuticals Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering SUPN?+
Among analysts who currently cover SUPN, David Amsellem of Piper Sandler has the strongest overall Quantellect track record (Rank #95). Their current call is Buy with a $65.00 target.
What is Supernus Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.66 per share (range $0.59 – $0.74) across 3 analysts. Full-year EPS is projected at $2.49, rising to $4.34 the following year.
How much revenue is Supernus Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $219.0M (range $211.0M – $223.3M). Full-year revenue is projected at $867.2M, growing to $1.0B next year.
Have analysts been upgrading or downgrading SUPN lately?+
As of Jul, 4 of 5 firms rate SUPN a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their SUPN calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
